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Abstract
Bone loss and alterations in bone quality are major causes leading to bone fragility in postmenopausal
women. Although bisphosphonates are well known to reduce bone turnover and prevent bone loss
in postmenopausal osteoporosis, their effects on other bone properties are not fully characterized.
Changes in bone mineral and matrix properties may contribute to the anti-fracture efficacy observed
with bisphosphonate treatments. The aim of this work was to analyze the effect of a one-year
treatment with either alendronate or risedronate, at low and high doses, on spatially resolved bone
material and compositional properties that could contribute to the fracture efficacy of these agents.
Distal tibias from thirty normal beagles that had been treated daily for one year with oral doses of
vehicle (Veh), alendronate (Aln) at 0.2 or 1 mg/kg, and risedronate (Ris) at 0.1 or 0.5 mg/kg were
analyzed by Fourier Transform Infrared imaging (FTIRI) to assess the changes in both mineral and
matrix properties in discrete bone areas. The widths at half maximum of the pixel histograms for
each FTIRI parameter were used to assess the heterogeneity of the bone tissue.
Aln and Ris increased the mineral content and the collagen maturity mainly in cancellous bone and
at the endocortical surface. Significant differences were observed in the mineral content and in the
hydroxyapatite crystallinity distribution in bone tissue, which can contribute to reduced ductility and
micro-crack accumulation. No significant differences were observed between low and high dose nor
between Aln and Ris treatments.
These results show that pharmacologic suppression of bone turnover increases the mineral and matrix
bone tissue maturity in normal cancellous and endocortical bone areas where bone turnover is higher.
These positive effects for decreased fracture risk are also associated with a loss of bone heterogeneity
that could be one factor contributing to increased bone tissue brittleness and micro-crack
accumulation.
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Introduction
The fragility of bone is determined by the quantity of bone present, usually measured in terms
of bone mass, or bone mineral density (BMD), and also by the quality of the bone. Bone quality
refers to the bone composition and structure that contribute to bone strength independent of
BMD. Bone quality may include bone microarchitecture, mineralization, mineral and matrix
composition, and the distribution of micro-cracks [1-7]. Although it is well-accepted that
mineral and matrix bone properties contribute to bone's fracture resistance, their precise effect
on bone mechanical properties remains unknown. While several studies have shown efficacy
of anti-resorptive agents like alendronate (Aln) and risedronate (Ris) in preventing bone
fragility in postmenopausal osteoporosis and other metabolic bone diseases and in metastatic
bone cancer by increasing BMD [8-15], the observed changes in BMD following
bisphosphonate treatment are not sufficient to explain the reduction in fracture risk in these
patients [16]. Indeed, an increase in BMD is not necessarily associated with a reduction of
fracture risk, as shown by the BMD increases with the fluoride therapy [17]. Other
compositional and structural factors independent of BMD alter bone quality and could be
associated with fracture reduction [18]. These factors have to be analyzed to fully understand
the mechanisms for the benefit of bisphosphonate treatment and its effects on the bone tissue
properties.
Mineral content and collagen matrix structure contribute significantly to mechanical bone
properties and fracture resistance [5,7,18]. The bone organic matrix is predominantly type I
collagen. Following secretion from the cell, collagen undergoes numerous post-translational
modifications which play an important role in matrix mineralization, and with time the collagen
is stabilized by a cross-linking network [18,19]. The mineralization process consists of primary
mineral deposition in the collagen matrix scaffold followed by a slow and progressive mineral
deposition called secondary mineralization. With aging, tissue mineralization, collagen
maturity, and collagen cross-linking increase [20-23]. These changes tend to stabilize the
collagen network, increasing stiffness but also reducing the ductility of the tissue [5,19,24].
In humans, bisphosphonates reduce fracture risk in osteoporotic women and men [10,11,25,
26] by suppressing bone turnover through inhibition of osteoclast-mediated resorption [27]. In
this way, they slow the rate of bone loss and increase the BMD [9]. Recently it was also found
that the bisphosphonates induced differences in the maturation profile of collagen [18,28]. A
study using FTIR imaging (FTIRI), a technique that analyzes the compositional changes in
bone tissue with ~7μm spatial resolution, showed the cortical bone was more mineralized in
Aln-treated postmenopausal iliac crest compared to the placebo [29] but found no significant
changes in collagen maturity. A decrease in the variation (heterogeneity) of all of the measured
FTIRI parameters including collagen maturity was also noted with Aln treatment. This led us
to posit that bisphosphonate treatment, in addition to aging and osteoporosis, narrowed the
heterogeneity of numerous tissue-level parameters. To address the effects of bisphosphonates
on these properties, independent of aging and osteoporosis, we chose to study tissue from non-
ovariectomized bisphosphonate-treated and control dogs.
In the dog model, studies using biochemical analyses reported that bisphosphonates
significantly alter the organic matrix by increasing collagen maturity [30,31]. A one-year
treatment of Ris or Aln, at doses at or above those used for treatment of osteoporosis, suppressed
bone remodeling, and increased mineral content and vertebral stiffness [32-34]. These doses
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not only affect the mineral fraction of bone, but also significantly increased collagen cross-
linking (both enzymatic and non-enzymatic types) and collagen isomerization [30]. On the
other hand this remodeling suppression also significantly increased micro-damage
accumulation and decreased some mechanical properties in dog bones [35-38]. Although
FTIRI is a useful tool to assess changes in mineralization or collagen cross-link maturity in
bone tissue [23] no modifications were observed in cortical bone from dogs treated with high
doses of bisphosphonates [33].
Lack of agreement between chemical and spectroscopic measurements of collagen maturity
and between data in osteoporotic humans [29,39] and within the non-osteoporotic preclinical
models led us to hypothesize that these differences, in addition to being related to the initial
status of the bone (osteoporotic or normal), were species, site, drug, and technique dependent.
To address this hypothesis this study used FTIRI to compare the spatial variation of mineral
and matrix properties in response to suppression of remodeling caused by one-year treatment
of normal dogs with either alendronate or risedronate in specific bone areas.
Materials and Methods
Tibias from thirty female beagles (average age at sacrifice 2.3 ±0.02 years) used in a previous
experiment [34] were cleaned of soft tissue. The dogs had been purchased from Marshall Farms
USA (North Rose, NY), acclimated for a period of 1 month, housed two per cage in
environmentally controlled rooms, and fed standard dog chow. Water was available at all times.
Drug administration was done approximately 2 h before feeding. All procedures were in
accordance with approved NIH guidelines, under a protocol approved by the Indiana University
School of Medicine Animal Care and Use Committee. The dogs had been assigned to treatment
groups (n= 6/group) by matching body weights. All dogs were treated daily for 1 year with
oral doses of vehicle (Veh), risedronate (Ris, 0.1 or 0.5 mg/kg/day; Procter and Gamble
Pharmaceuticals), or alendronate (Aln, 0.2 or 1 mg/kg/day; Merck). Doses of each
bisphosphonate for the high-dose group were 5-6 times greater, calculated on a mg/kg basis,
than the clinical doses used for osteoporosis treatment in humans. At the end of the experiment,
dogs were killed by an overdose of a sodium pentobarbital derivative (0.22 mg/kg
intravenously, Beuthanasia-D Special; Schering-Plough Animal Health Care Co., Kenilworth,
NJ).
Tibias were fixed in alcohol and embedded in polymethylmethacrylate (PMMA). They were
cut at 2-3 microns thickness and mounted on barium fluoride infrared windows (SpectraTech,
Hopewell Junction, NY). The undecalcified sections were examined using a Perkin Elmer
Spotlight 300 Infrared Imaging system (Perkin Elmer Instruments, Waltham, MA, USA) at a
spectral resolution of 4 cm−1. Mineral and matrix properties were assessed using Fourier
transform infrared microscopic imaging (FTIRI) in four specific regions of the tibial cross-
sections (Figure 1): cancellous bone, the endocortical third of the cortex (interior cortical),
mid-cortex, and the periosteal third of the cortex (exterior cortical). For each bone area, three
different images were recorded. Means and standard deviations for the three images in each
bone area were calculated and compared. The values were then averaged for each group. The
cross-sections were processed for FTIRI in a blinded fashion and the codes identifying groups
not broken until the time of statistical analysis. Background (BaF2 window only) and PMMA
spectra were collected for each section analyzed for correction of the sample spectral data using
ISYS software (Spectral Dimensions, Olney, MD). Spectra were baseline corrected and the
PMMA spectral contribution subtracted using ISYS software as previously described in detail
[40]. FTIR parameters reviewed in detail elsewhere [41,42] were calculated using ISYS
software. The mineral/matrix ratio, which measures bone mineral content (correlated to ash
weight) was calculated from the integrated areas of phosphate (916-1180 cm−1) to Amide I
(1592-1712 cm−1). The collagen cross-linking network maturity (XLR) was estimated as the
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peak intensity ratio of Amide I subbands at 1660 and 1690 cm−1. The carbonate/phosphate
ratio, which reflects the level of carbonate substitution in the hydroxyapatite (HA) crystal was
calculated as the integrated area of the ν2 carbonate peak (840-892 cm−1) to that of the
phosphate. The HA crystallinity, related to mineral crystal size and perfection as determined
by x-ray diffraction, was calculated as the phosphate subband 1030/1020 cm−1 peak intensity
ratio. For each FTIRI parameter, bone heterogeneity was calculated as the full width at half
maximum (FWHM) using the pixel histogram distribution (Figure 4A) in both cancellous and
cortical bone.
All statistical analyses were performed with SigmaStat (Systat Software Inc, San Jose, CA,
USA). One-way ANOVAs were used to compare the treated groups to VEH, and to evaluate
dose-responses. Statistical significance was based on the Dunnett's test and defined as
p<0.05.
Results
Typical FTIRI images recorded in the endocortical bone region are illustrated for one dog (A)
from the control group and one (B) from the group treated with 0.5mg/kg/day of Risedronate
(Figure 2). In the cancellous bone mean values for mineral/matrix ratio were higher in all the
bisphosphonate groups than in vehicle-treated dogs (p<0.05; Figure 3). For Aln, levels for the
Mineral/Matrix ratio were 13% (0.2 mg/kg) and 14% (1 mg/kg) higher than Veh (p<0.001).
For Ris, Mineral/Matrix ratios were 11% (0.1 mg/kg, p < 0.05) and 14.5% (0.5 mg/kg, p <
0.001) higher than Veh. No significant differences were found between the dose-equivalents
of the two bisphosphonates, or for different doses within each drug. The Mineral/Matrix ratio
calculated from the bisphosphonate groups were not significantly different compared to control
in the cortical region (data not shown) considered in its whole. When calculated in specific
regions of the cortex (Figure 1) the Mineral/Matrix ratio was 6-8% higher in Ris and Aln than
Veh (p<0.05) in the endocortical third of the cortex. For both mid-cortex and outer cortex no
significant differences were observed in the mineral content among groups.
All bisphosphonate-treated groups had a significantly higher collagen crosslink ratio (XLR)
compared to vehicle treated controls in all bone areas analyzed, except for the lowest dose of
Aln in the outer third of the cortex (Figure 3). XLRs was 10-17% higher in the cancellous and
endocortical regions of the cortex (P<0.001), but only 7-8% higher in the mid-cortex (p<0.05),
where bone turnover is slower. The smallest increases were found near the periosteal surface
(4-8%, p < 0.05). There were no dose-dependent differences in XLR in either Aln or Ris treated
groups.
The Carbonate/phosphate ratio and the crystallinity ratio did not show any significant
differences in either alendronate- or risedronate-treated dog groups compared to the Veh
(Figure 3).
Bone heterogeneity was assessed by the FWHM calculated from the pixel histograms for each
individual image as illustrated in Figure 4A. The width of the FWHM reflecting the bone
heterogeneity for each FTIRI parameter decreased significantly for the mineral/matrix ratio
and crystallinity in both Aln and Ris-treated groups compared to Veh for each of the bone areas
analyzed. For the carbonate/phosphate ratio a significant decrease in the FWHM was observed
only for Ris 0.1 in cortical bone. Concerning XLR, a decrease in FWHM was noted only for
the Aln 0.2 group in cancellous bone compared to the control. FWHM was higher in all groups
in cancellous bone compared to cortical bone for each FTIRI parameter (p<0.001). There were
no dose dependent differences in bone heterogeneity for any of the IR parameters analyzed in
either alendronate or risedronate treated groups, nor were there differences between
alendronate and risedronate-treated groups at equi-potent doses.
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Discussion
FTIRI analysis showed there was significantly higher mineral content and cross-linking
maturity in cancellous and cortical bone in canine tibiae of normal dogs treated with Aln or
Ris independent of dosage. In terms of mineral content, the previous work based on FTIR
analysis to understand the effects of bisphosphonate treatments on bone tissue did not give
consistent results. In some studies FTIR spectroscopic parameters of bone treated with
bisphosphonates were found to be comparable to control animals as shown in a study of
trabecular bone in ovariectomized rats treated with tiludronate [43] as well as in a study of
cortical bone from normal dogs treated with high doses of Aln or Ris [33]. Recently, Boskey
et al. found by FTIRI analysis that the mineral content in postmenopausal women was
significantly increased by Aln treatment in cortical bone but not in cancellous bone [29]. This
difference between cancellous and cortical bone modification following bisphosphonate
treatment is surprising because one would expect a greater increase from suppressing bone
turnover in areas of more rapid remodeling (i.e., cancellous bone) than in areas with pre-
existing low remodeling (ie cortical bone) [36]. Suppression of bone turnover by
bisphosphonates along with increases in the mineral content in both cortical and trabecular
bone area is consistent with several studies in ovariectomized rodents and normal dogs [31,
34,44]. This increase in mineral content can be linked to a significant increase in the structural
mechanical properties of bone treated with bisphosphonates in these animal models [32,44,
45]. In this dog model, higher bone mineral content has been found in the vertebrae, ribs and
iliac crest from dogs treated with high doses of Aln or Ris, based on pQCT, ash fraction or
density fractionation data [33,34], while FTIRI data did not show any mineral or matrix
modifications linked with the bisphosphonate treatments. This discrepancy in FTIRI results
between the previous and current work is most likely attributable to the examination of whole
cortex of bone in the previous study rather than distinct bone areas as was performed in the
current work. Although Aln has a higher affinity for bone-like carbonated apatite than
risedronate [46,47] and should bind to more sites on the mineral crystals in the normal dog, no
significant differences were observed in the bone properties recorded by FTIRI in our study.
Differences in binding affinities between Aln and Ris must play a role mainly in how these
drugs are retained in the skeleton and influence the persistence of the drug effect.
Durchschlag et al [48] showed through FTIRI analysis of replicate biopsies from risedronate-
treated osteoporotic women, that bisphosphonate treatment maintained, but did not increase,
the maturity of the collagen cross-link network in cancellous bone. Likewise, Boskey et al
[29] did not find any changes in the collagen maturity by FTIRI in healthy postmenopausal
women treated with Aln compared to the placebo. These observations contrast with data from
several independent studies in human [28] and canine models which found, by biochemical
analyses, that treatment with bisphosphonates resulted in collagen maturity changes in bone
tissue [30,31]. Our results in the normal canine, coupled with earlier chemical analyses of
collagen cross-linking and isomerization in the vertebral bodies of these dogs [30] confirm that
collagen maturity is modified by bisphosphonates in both cortical and trabecular bone of
normal animals and we show that a part of these modifications can be spatially analyzed by
FTIR imaging. The intermolecular cross-linking of collagen is a chemical feature that
contributes to the arrangement of collagen molecules in the fibril which provides fibrillar
matrices with important mechanical properties for bone tissue. We cannot compare directly
the data for the maturity of collagen obtained by FTIRI and biochemical analysis, indeed, the
ratio (1660/1690) calculated by FTIRI is an indicator of the environment in which cross-links
exist, and these have been correlated with relative amounts of mature and immature enzymatic
cross-links [22] whereas the chemical analyses based on methods such as HPLC quantifies the
different types of cross-links, including those which are formed by enzymatic and non-
enzymatic processes [18], and is likely to be more sensitive. Recently, it was shown the cross-
link ratio obtained by FTIRI increases with tissue age and can be correlated with the mechanical
Gourion-Arsiquaud et al. Page 5
Bone. Author manuscript; available in PMC 2011 March 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
properties of bone [23]. The present results indicate that the changes in the enzymatic cross-
link maturity from bisphosphonate treatment may play a role in the decreased fracture risk
associated with these treatments. However, as bone collagen is not only post-translationally
modified by enzymatic cross-linking, but also affected by non-enzymatic glycation and β-
isomerization [18] the exact effects of bisphosphonate drugs on bone matrix and their
consequences on the mechanical properties is unknown, since all of these modifications may
coexist. Recently it was found that the reduction in bone turnover by bisphosphonate treatments
increases advanced glycation end-products (AGEs, non-enzymatic cross-links) in bone tissue
[18,30,31,38] and this accumulation of AGEs could be associated with reduced tissue-level
fracture resistance [38,49].
When bone properties were assessed by FTIRI in cortical bone of the iliac crest (without
cancellous bone), no significant changes between control and Aln or Ris groups were detected
[33]. On the other hand, as shown in our study, when FTIR parameters are measured in specific
cortical areas we observed the endocortical area presents the same bone property modifications
as those observed in the cancellous bone. The changes resulting from bisphosphonate treatment
are very important in the cancellous area which is altered during osteoporosis [6] and in the
endocortical area where the cortical bone loss is accelerated in postmenopausal women [50,
51]. This may help to explain the specific positive effect of these drugs in postmenopausal
osteoporosis or osteogenesis imperfecta in children in which there is high turnover in
cancellous and endocortical regions [52,53]. These results show clearly that bone properties
are not uniformly modified by the bisphosphonates and that the FTIRI is a discerning tool to
analyze specific areas in very heterogeneous biologic tissues like bone. In studies dealing with
efficacy of therapies, some relevant information may be lost when properties of the cancellous
and endocortical surface bone parts are coaveraged with those from bulk cortical bone.
We were unable to detect a significant dose dependent effect or differences between the effects
of the two different bisphosphonates tested on the observed FTIRI parameters of bone quality.
It is possible that the small number of samples analyzed prevented us from detecting a
significant effect.
Interestingly, while crystallinity was not significantly modified by bisphosphonates and the
mineralization of the bone was only affected in the cancellous and endocortical regions, we
found a significant decrease in the distribution of these parameters (heterogeneity) in both
cortical and cancellous bone. These data are in agreement with recent FTIRI work on
alendronate-treated postmenopausal women [29] where a loss of compositional heterogeneity
was associated with antiresorptive treatment, and suggests that the observation of decreased
heterogeneity in that study may be related to the antiresoprtive effects of the drug rather than
to disease state alone. This effect is not surprising as bone heterogeneity is a product of bone
remodeling which is significantly reduced by bisphosphonates. The homogenization of the
mineral content and the crystallinity reflects a more static bone tissue in the bisphosphonate-
treated normal dog. The decrease is especially significant in cancellous bone. As healthy
cancellous bone is characterized by a broad heterogeneity, there is evidence that the
homogenization of the cancellous bone affects the mechanical properties of the whole bone
[54,55]. Although the exact impact of changes in bone heterogeneity on mechanical bone
properties has not been analyzed directly, the loss of heterogeneity could be one factor that
contributes to increased brittleness of bisphosphonate treated tissues [56]. We propose that the
controversy concerning the benefit of long bisphosphonate treatment times compared to shorter
treatment times of <5 years [57-59] and the unusual shaft fractures in long bone observed in
few cases during long term bisphosphonate therapy [60-62] might be explained by excessive
bone homogenization. To confirm this hypothesis it will be important in the future to analyze
the bone heterogeneity changes with bisphosphonate use as a function of the duration of
treatment as it may play a significant role in the prevention of crack initiation and propagation
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processes during cyclic loading and fatigue [63,64]. The bone homogenization observed in this
work with bisphosphonate could be correlated to the significant accumulation of micro-damage
observed in the vertebra of the same canine model after 1 year of bisphosphonate treatment
[32,34]. It thus appears important to consider more carefully bone tissue heterogeneity as a
new important bone quality factor when analyzing the effects of therapy duration or dose on
bone properties.
This study had several limitations. First, the dogs used in the study were not osteoporotic as
ovariectomy alone in dogs does not cause bone loss. Second, the higher dose of drug given to
the dogs was 5-6x higher than the clinical dose given to postmenopausal women, on a mg/kg
basis. Third, even those doses considered to be equivalent to the clinical dose did not take into
account species differences in the pharmacokinetics or pharmacodynamic properties, or species
differences in bioavailability of the drug.
Nevertheless, the FTIRI data show that both pharmacologic and suprapharmacologic doses of
bisphosphonates are associated with similar bone quality modifications in normal canines. Aln
and Ris increased the mineral and matrix bone maturity most in higher turnover areas
(cancellous and endocortical surfaces) that are more greatly influenced by remodeling
suppression. Increased mineralization and enhanced maturity of the organic matrix structure
have positive influences on the biomechanical properties of bone which contribute to reduction
of fracture risk, but the bone homogenization observed with bisphosphonate use suggests that
these drugs also could have negative effects on bone quality. The effectiveness and the safety
of the bisphosphonates use are well accepted however a better understanding of the effects of
long-term bisphosphonate therapy on bone properties could improve decision in many clinical
practice guidelines.
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Figure 1.
For each dog cross-section 12 images (black squares) recorded by FTIR imaging were analyzed
from 4 different bone areas; 3 in cancellous, 3 in the inner third of the cortex, 3 in mid-cortex,
and 3 in the outer third of the cortex.
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Figure 2.
Typical Infrared images for the Mineral/Matrix ratio, cross-link maturity (XLR), Carbonate/
Phosphate ratio and crystallinity ratio recorded from the endocortical third of the cortex in the
control group (A) and the 0.5 mg/kg/day risedronate-treated group (B). Note in these figures
1 pixel = 6.25×6.25 μm.
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Figure 3.
Changes in mineral and matrix bone properties with anti-remodeling agents calculated by FTIR
at different bone locations. Data presented as mean ± SD. (a) p<0.001 and (b) p<0.05 versus
vehicle within each region.
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Figure 4.
Bone heterogeneity was assessed by the FWHM of pixel distribution (A) from each FTIR
image. FWHM was calculated for each FTIR parameter in both cancellous and cortical bone
for each group (B). Data presented as mean ± SD. (a) p<0.001 and (b) p<0.05 versus vehicle.
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